Skip to main content
. 2018 May 25;62(6):e00082-18. doi: 10.1128/AAC.00082-18

FIG 5.

FIG 5

In vitro combination of AB-423 with nucleos(t)ide analogs and RNAi agents. Panels I, checkerboard synergy plots based on MacSynergy II analysis; panels II, antiviral dose-responses of each agent tested singly and in combination. (A) In vitro combination of AB-423 and ETV (AML12-HBV10 cell rcDNA/bDNA assay); (B) in vitro combination of AB-423 with the RNAi agent ARB-1467 (AML12-HBV10 cell rcDNA/bDNA assay); (C) in vitro combination of AB-423 with the RNAi agent ARB-1740 (AML12-HBV10 cell rcDNA/bDNA assay); (D) in vitro combination of AB-423 with TDF (HepDE19 cell rcDNA/bDNA assay); (E) in vitro combination of AB-423 with ETV (HepBHAe82 cell pcRNA/cccDNA assay); (F) in vitro combination of AB-423 with ARB-1740 (HepBHAe82 cell pcRNA/cccDNA assay). The results shown are the averages for quadruplicate samples.